Expertise in
2
conditions

Lionel Uwer

Vandoeuvre-les-nancy, FR 
Expertise in
2
conditions
Vandoeuvre-les-nancy, FR 

Overview

Lionel Uwer practices practicing medicine in Vandoeuvre-les-nancy, France.

Mr. Uwer is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Breast Cancer in Men, Agranulocytosis, and Small Cell Lung Cancer (SCLC).

He is actively involved in clinical research, co-authoring 50 peer reviewed articles and participating in 7 clinical trials.

Gender

Male

Locations

Vandoeuvre-les-nancy, France
Other Locations
Nancy, France
1 Rue Du Général Koenig, Reims, 51100, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Adjuvant Systemic Treatment for Oestrogen-receptor (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment. A French UNICANCER Geriatric Oncology Group (GERICO) and Breast Group (UCBG) Multicentre Phase III Trial
Adjuvant Systemic Treatment for Oestrogen-receptor (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment. A French UNICANCER Geriatric Oncology Group (GERICO) and Breast Group (UCBG) Multicentre Phase III Trial
Enrollment Status: Completed
Publish Date: July 20, 2026
Intervention Type: Drug
Study Drugs: Hormonotherapy, Chemotherapy then Hormonotherapy
Study Phase: Phase 3
Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival
Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival
Enrollment Status: Completed
Publish Date: April 17, 2026
Intervention Type: Other
Study Phase: Phase 4
Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation (CHACRY-1501)
Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation (CHACRY-1501)
Enrollment Status: Active_not_recruiting
Publish Date: March 18, 2026
Intervention Type: Procedure
Study Phase: Not Applicable
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Enrollment Status: Completed
Publish Date: June 03, 2024
National Retrospective Study to Characterize LOng REsponder Under EribuLINE (HALAVEN®) Metastatic Breast Cancer Patients
National Retrospective Study to Characterize LOng REsponder Under EribuLINE (HALAVEN®) Metastatic Breast Cancer Patients
Enrollment Status: Completed
Publish Date: April 05, 2021
Intervention Type: Other
A Phase II Study of Eribulin in Brain Metastases From HER2-negative Breast Cancer Pre-treated With Anthracyclines and Taxanes
A Phase II Study of Eribulin in Brain Metastases From HER2-negative Breast Cancer Pre-treated With Anthracyclines and Taxanes
Enrollment Status: Withdrawn
Publish Date: May 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
Prospective Study Assessing the Impact of RNA Genomic Profile Defined by a Genomic Test on Treatment Decision-making in Breast Cancer Patients With an ISH Equivocal HER2 Status- EQUIVOK Study
Prospective Study Assessing the Impact of RNA Genomic Profile Defined by a Genomic Test on Treatment Decision-making in Breast Cancer Patients With an ISH Equivocal HER2 Status- EQUIVOK Study
Enrollment Status: Terminated
Publish Date: July 25, 2019
Intervention Type: Diagnostic test
Study Phase: Not Applicable
View 6 Less Clinical Trials

50 Total Publications

Eribulin efficacy in long responder patients with metastatic breast cancer: A multicentric observational study.
Eribulin efficacy in long responder patients with metastatic breast cancer: A multicentric observational study.
Journal: Cancer epidemiology
Published: November 20, 2024

Frequently Asked Questions about Lionel Uwer

Is Lionel Uwer a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Lionel Uwer is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Lionel Uwer participate in research or clinical trials?

Yes. Lionel Uwer has published 50 articles and abstracts on conditions like Breast Cancer. You can view a list of Lionel Uwer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Uwer's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile